-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, SaJWmy8OR+AZ5wnu97NsjC3tFbkE2yN7U19aD2jjfFlrgPAzRo8Yi2tUD8R3WL5H ql02w76xYMu0cVKut1MCeg== 0000950123-10-003792.txt : 20100120 0000950123-10-003792.hdr.sgml : 20100120 20100120164216 ACCESSION NUMBER: 0000950123-10-003792 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100115 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20100120 DATE AS OF CHANGE: 20100120 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ROCKWELL MEDICAL TECHNOLOGIES INC CENTRAL INDEX KEY: 0001041024 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 383317208 STATE OF INCORPORATION: MI FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23661 FILM NUMBER: 10536657 BUSINESS ADDRESS: STREET 1: 30142 S WIXOM RD CITY: WIXOM STATE: MI ZIP: 48393 BUSINESS PHONE: 2489609009 MAIL ADDRESS: STREET 1: 30142 S WIXOM RD CITY: WIXOM STATE: MI ZIP: 48393 8-K 1 k48780e8vk.htm FORM 8-K e8vk
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 15, 2010
ROCKWELL MEDICAL TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
         
Michigan   000-23661   38-3317208
         
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)
         
  30142 Wixom Road, Wixom, Michigan   48393  
         
  (Address of principal executive offices)   (Zip Code)  
     
Registrant’s telephone number, including area code (248) 960-9009
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
     On January 15, 2010, the Compensation Committee of the Board of Directors of Rockwell Medical Technologies, Inc. (the “Company”) approved salary increases (effective January 16, 2010), discretionary cash bonuses for 2009 performance and stock option grants for the Company’s executive officers, as follows:
                                     
                New Annual   Prior Annual    
Executive   Position   Bonus   Salary   Salary   Option Grant
Robert Chioini
   Chief Executive Officer   $ 116,250     $ 495,000     $ 465,000     $ 150,000  
Thomas Klema
   Chief Financial Officer     68,750       295,000       275,000       60,000  
Dr. Richard Yocum
   VP Clinical Development     58,000       298,000       278,000       75,000  
Dr. Ajay Gupta
   Chief Scientific Officer     38,000       348,000       298,000       60,000  
     The stock options were granted under the Company’s 2007 Long Term Incentive Plan using the Form of Nonqualified Stock Option Agreement (Employee Version) previously disclosed and filed by the Company with the Securities and Exchange Commission on Form 8-K on December 20, 2007. The options have an exercise price of $7.13, the closing market price on January 15, 2010. The options become exercisable in three equal annual installments beginning January 15, 2011, and the options will become immediately exercisable upon a change in control of the Company or the recipient’s death or disability. The options will expire on January 15, 2020.

2

 

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  ROCKWELL MEDICAL TECHNOLOGIES, INC.
 		  
Date: January 20, 2010  By:   /s/ Thomas E. Klema    
    Thomas E. Klema   
    Its: Chief Financial Officer   
 

3

-----END PRIVACY-ENHANCED MESSAGE-----